STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more

Hey there, and happy Wednesday. STAT reporter Andrew Joseph here filling in for Mr.

Pharmalot. It’s already been a busy day here at STAT’s London outpost.

We hope wherever you are, you can find time to take a break for a snack or a walk. To the news we go.

… For biotech investors, the risks seen with the rise of the Make America Healthy Again movement are fading , the Wall Street Journal says. Robert F.

Kennedy Jr., a critic of the industry, is still health secretary, and MAHA still has sway over parts of the American public. But for Wall Street, the political risk of investing in drug companies has been demoted: It now sits well below interest rates, clinical data, and earnings in the hierarchy of concerns.

Recent ousters of U.S.